Pancreas Cancer News and Archives
	SuperGen Submits Second Module of Orathecin's(TM) 'Rolling' New Drug Application as an Oral Treatment for Pancreatic Cancer Dublin, California February 7, 2003 SuperGen Inc. announced today that it has submitted to the Food and Drug Administration (FDA) the second of three data modules of the New Drug Application (NDA) for its anticancer compound Orathecin(TM), an oral chemotherapy compound for the treatment of pancreatic cancer patients who are refractory (resistant) to available therapies. The submission is taking place on a 'rolling' basis with the first module, which contained the chemistry, manufacturing and controls (CMC) section, having been submitted on December 30, 2002. ...full article
	For educational purposes only; not to be relied upon Please read Pancreatica Disclaimer
	Home | In The News | Links | About Us | Donations FAQ | Clinical Trials Database | Research Resources
	webmaster
	©2000-2008 Pancreatica.org - All Rights Reserved www.pancreatica.org